Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.GLYC · Entity 5255 | Director | May 01, 2024 | May 01, 2024 |
| MACROGENICS INCMGNX · Entity 6104 | Director | May 18, 2026 | May 20, 2026 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date May 01, 2024 · Filed May 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.62 · Expires 2034-04-30 | Direct | 40,000 |
Reported balance
After 2024-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-01 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.
MACROGENICS INC
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,750 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Exercise / conversion · Acquired 3,750 · Balance 14,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,750 |
Reported balance
After 2026-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-19 · Grant · Acquired 3,750 · Balance 3,750 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2036-05-19 | Direct | 22,000 |
Reported balance
After 2026-05-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-19 · Grant · Acquired 22,000 · Balance 22,000 F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F2: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
F3: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
F4: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.
Spero Therapeutics, Inc.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,000 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 10,000 · Balance 85,000 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2036-06-23 | Direct | 20,000 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Grant · Acquired 20,000 · Balance 20,000 F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mural Oncology plc
Report date December 05, 2025 · Filed December 05, 2025
Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 8,637 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2034-05-29 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Disposition to issuer · Disposed 8,462 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2033-12-13 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-05 · Disposition to issuer · Disposed 15,021 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").
F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 25, 2026 22:57 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001193125-26-283202 · ownership.xml · derivative · entry 2 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-06-23 F2 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 22:57 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-283202 · ownership.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:14 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001566617-26-000002 · wk-form4_1779308045.xml · derivative · entry 4 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-19 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:14 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001566617-26-000002 · wk-form4_1779308045.xml · derivative · entry 3 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:14 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001566617-26-000002 · wk-form4_1779308045.xml · derivative · entry 2 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. F2 · derivative.expiration_date: The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:14 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001566617-26-000002 · wk-form4_1779308045.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 09:01 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 15,021 | Not disclosed Strike: $3.61 | Not disclosed |
DisclosureSEC source: 0001193125-25-308773 · ownership.xml · derivative · entry 3 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,021 shares Expires 2033-12-13 F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 09:01 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 8,462 | Not disclosed Strike: $3.35 | Not disclosed |
DisclosureSEC source: 0001193125-25-308773 · ownership.xml · derivative · entry 2 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 09:01 UTC | Mural Oncology plc MURA · Entity 72153 | Disposition to issuerStock Option (right to buy) · Derivative | 8,637 | Not disclosed Strike: $2.56 | Not disclosed |
DisclosureSEC source: 0001193125-25-308773 · ownership.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,637 shares Expires 2035-06-10 F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time"). F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:29 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087017 · ownership.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 12, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 08:00 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 8,637 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0000950170-25-085819 · ownership.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,637 Underlying: Ordinary Shares · 8,637 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2025. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:03 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001125345-25-000083 · wk-form4_1747944173.xml · derivative · entry 4 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-05-21 F4 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2025 Filed May 22, 2025 20:03 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000083 · wk-form4_1747944173.xml · derivative · entry 3 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:03 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 6,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-25-000083 · wk-form4_1747944173.xml · derivative · entry 2 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. F2 · derivative.expiration_date: The RSUs vested on May 20, 2025, which was one day prior to the Issuer's 2025 Annual Meeting of Stockholders held on May 21, 2025. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:03 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 6,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001125345-25-000083 · wk-form4_1747944173.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 10:14 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 8,462 | $3.35 Strike: $3.35 | $28,347.70 |
DisclosureSEC source: 0000950170-24-067707 · ownership.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document |
| May 30, 2024 Filed Jun 5, 2024 16:10 UTC Amendment | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 8,462 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000950170-24-069314 · ownership.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,462 Underlying: Ordinary Shares · 8,462 shares Expires 2034-05-29 F2 · price: This amendment to Form 4 is being filed solely to correct the price of the derivative security, which was previously reported as being $3.35 due to a scrivener's error. F1 · derivative.exercise_date: This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:27 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066652 · ownership.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on May 29, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:16 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001125345-24-000126 · wk-form4_1716498951.xml · derivative · entry 2 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-05-21 F3 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:16 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 6,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000126 · wk-form4_1716498951.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F2 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:34 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000107 · wk-form4_1716410040.xml · derivative · entry 2 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. F2 · derivative.exercise_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. F2 · derivative.expiration_date: The RSUs vested on May 20, 2024, which was one day prior to the Issuer's 2024 Annual Meeting of Stockholders held on May 21, 2024. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:34 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-24-000107 · wk-form4_1716410040.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock unit (RSU) grant was approved by the Board of Directors on May 31, 2023. Each RSU represents a contingent right to receive one share of the Issuer Common Stock. Read SEC document |
| May 01, 2024 Filed May 1, 2024 20:25 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001415889-24-011861 · form4-05012024_080513.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 16:30 UTC | Mural Oncology plc MURA · Entity 72153 | GrantStock Option (right to buy) · Derivative | 15,021 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0000950170-23-071110 · ownership.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,021 Underlying: Ordinary Shares · 15,021 shares Expires 2033-12-13 F1 · derivative.exercise_date: This option was granted on December 14, 2023. This option shall vest over three years in twelve equal quarterly installments on each quarterly anniversary of October 31, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 21:19 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-052693 · ownership.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on October 5, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:57 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000098 · wk-form4_1685739418.xml · derivative · entry 2 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer?s Common Stock. The RSU grant was approved by the Issuer?s Board of Directors on May 31, 2023 and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2023 Equity Incentive Plan. F3 · derivative.exercise_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier F3 · derivative.expiration_date: The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:57 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001125345-23-000098 · wk-form4_1685739418.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:18 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001209191-23-031443 · doc4.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-05-18 F1 · derivative.exercise_date: The shares underlying this option vest on May 19, 2024, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 21:45 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-031505 · doc4.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on September 15, 2023, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 19, 2022 Filed May 24, 2022 01:07 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001125345-22-000065 · wf-form4_165335440496083.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:10 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-030982 · doc4.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: The shares underlying this option vest on May 18, 2023, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 20:48 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0000899243-21-033460 · doc4.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:55 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-21-036382 · doc4.xml · derivative · entry 2 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2031-05-17 F3 · derivative.exercise_date: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 18, 2021 Filed May 28, 2021 00:55 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036382 · doc4.xml · nonDerivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · security: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · shares: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 13, 2021 Filed May 18, 2021 01:28 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $28.88 | $0.00 |
DisclosureSEC source: 0001125345-21-000074 · wf-form4_162130130131615.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 21:34 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.52 | $0.00 |
DisclosureSEC source: 0000899243-20-029333 · doc4.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-10-27 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on October 27, 2021 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 23, 2020 Filed Jun 23, 2020 21:33 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.94 | $0.00 |
DisclosureSEC source: 0000899243-20-017496 · doc4.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: The shares underlying this option will vest in thirty-six equal monthly installments at the end of each successive month following June 23, 2020, subject to the Reporting Person's continued service as a director through the applicable vesting dates. Read SEC document |
| May 22, 2020 Filed May 27, 2020 20:29 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032304 · doc4.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The shares underlying this option vest on May 22, 2021, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 14, 2020 Filed May 15, 2020 20:37 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $24.97 | $0.00 |
DisclosureSEC source: 0001125345-20-000091 · wf-form4_158957503190453.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-14 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 17, 2019 Filed May 21, 2019 20:04 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $12.39 | $0.00 |
DisclosureSEC source: 0001209191-19-031714 · doc4.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares underlying this option vest on May 17, 2020, subject to the reporting person's continuous service as of such vesting date. Read SEC document |
| May 16, 2019 Filed May 20, 2019 21:47 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001125345-19-000073 · wf-form4_155838886506188.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 00:01 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $11.52 | $0.00 |
DisclosureSEC source: 0001209191-18-060160 · doc4.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2028-11-26 F1 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The shares underlying this option vest in three equal installments on November 27, 2019, 2020 and 2021, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:53 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001125345-18-000069 · wf-form4_152693598301732.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-17 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:02 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000080 · wf-form4_149549416283411.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| January 24, 2017 Filed Jan 25, 2017 22:56 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.52 | $0.00 |
DisclosureSEC source: 0001125345-17-000012 · wf-form4_148538496854009.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: The option will vest 1/12th of the shares monthly, beginning on the first monthly anniversary of the grant date and will become fully exercisable 1 year from the date of grant (1/24/18). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.